Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-18
DOI
10.3389/fphar.2019.00671
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
- (2018) A. Barré et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease
- (2018) Brian G. Feagan et al. GASTROENTEROLOGY
- Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
- (2018) Renaud Gaujoux et al. GUT
- Anti-integrin therapy for inflammatory bowel disease
- (2018) Sung Chul Park et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients
- (2018) Cristiano Pagnini et al. Gastroenterology Research and Practice
- Natalizumab in the treatment of Crohn’s disease patients
- (2017) Cristiano Pagnini et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Primary and secondary nonresponse to infliximab: mechanisms and countermeasures
- (2017) Uni Wong et al. Expert Opinion on Drug Metabolism & Toxicology
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
- (2017) Silvio Danese et al. GUT
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
- (2017) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases
- (2017) Sebastian Zundler et al. INFLAMMATORY BOWEL DISEASES
- P209 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of GEMINI 1 completers rolling into the GEMINI open-label extension study
- (2017) E.V. Loftus et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease
- (2017) Nathaniel R West et al. NATURE MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sphingosine-1-Phosphate Signaling in Inflammatory Bowel Disease
- (2017) Ole Haagen Nielsen et al. TRENDS IN MOLECULAR MEDICINE
- Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
- (2017) Marcel Vetter et al. Therapeutic Advances in Gastroenterology
- Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis
- (2016) E. J. Mao et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
- (2016) Gaik W. Tew et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease
- (2016) Kelly A. Shaw et al. Genome Medicine
- Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
- (2016) Adrian D. Vickers et al. PLoS One
- Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
- (2015) Robert Hirten et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
- (2015) Glen S. Hazlewood et al. GASTROENTEROLOGY
- Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
- (2015) Walter Reinisch et al. GUT
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel Disease
- (2015) KO Arseneau et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease
- (2014) R. W. Stidham et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Biological Agents for Moderately to Severely Active Ulcerative Colitis
- (2014) Silvio Danese et al. ANNALS OF INTERNAL MEDICINE
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
- (2014) Michel Varrin-Doyer et al. EXPERIMENTAL NEUROLOGY
- Safety considerations when using anti-TNFα therapy to treat Crohn’s disease
- (2014) Cristiano Pagnini et al. Expert Opinion On Drug Safety
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
- (2014) Silvio Danese et al. GUT
- A phase II study of laquinimod in Crohn's disease
- (2014) Geert D'Haens et al. GUT
- Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease
- (2014) Wenyu Jiang et al. INFLAMMATION RESEARCH
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysis
- (2014) Siddharth Singh et al. MAYO CLINIC PROCEEDINGS
- In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease
- (2014) Raja Atreya et al. NATURE MEDICINE
- Vercirnonfor the treatment of Crohn's disease
- (2013) Kristen O Arseneau et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Mucosal healing in inflammatory bowel diseases: a systematic review
- (2012) Markus F Neurath et al. GUT
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Ulcerative colitis
- (2012) Ingrid Ordás et al. LANCET
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Fingolimod for Multiple Sclerosis
- (2012) Daniel Pelletier et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡
- (2010) Ingrid Arijs et al. INFLAMMATORY BOWEL DISEASES
- The potential for disease modification in Crohn's disease
- (2010) G. Van Assche et al. Nature Reviews Gastroenterology & Hepatology
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
- (2009) I. Arijs et al. GUT
- Inflammatory Bowel Disease
- (2009) Clara Abraham et al. NEW ENGLAND JOURNAL OF MEDICINE
- Probiotics promote gut health through stimulation of epithelial innate immunity
- (2009) C. Pagnini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
- (2009) Corey A. Siegel et al. Therapeutic Advances in Gastroenterology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started